Top Markets
Coin of the day
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc.

AZRX
Classement en actions #35193
AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12... AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).
Prix de l'action
$3.45
Dernière synchronisation: 2021-09-21
Capitalisation boursière
$4.29M
Changement (1 jour)
2.07%
Changement (1 an)
0.00%
Pays
US
Échange AzurRx BioPharma, Inc. (AZRX)

Catégorie

Ratio P/B pour AzurRx BioPharma, Inc. (AZRX)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de AzurRx BioPharma, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour AzurRx BioPharma, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE